EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Ji Woong Roh iD, Oh-Hyun Lee iD, Yongcheol Kim iD, Seok-Jae Heo iD, Eui Im iD, Deok-Kyu Cho iD

Korean Circulation Journal · 2026 · 56 (4) · 344

DOI: 10.4070/kcj.2025.0315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Circulation Journal, 2026. Verfasst von Ji Woong Roh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Yongin Severance Hospital, Yonsei University College of Medicine, Yon…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daewoong Pharmaceutical Co., LTD..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Rapid reduction of low-density lipoprotein cholesterol (LDL-C) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) is critical but challenging. This study evaluated the efficacy and safety of early triple lipid-lowering therapy with evolocumab, a moderate-intensity statin, and ezetimibe in statin-naïve ACS patients. METHODS: The C-STAR trial (Effect of Early Initiation of Evolocumab on Lipid Profile Changes in Patients with ACS Undergoing PCI) was a single-center, randomized, open-label trial conducted from December 2022 to January 2025. A total of 108 statin-naïve ACS patients undergoing PCI were randomized to evolocumab (140 mg) plus rosuvastatin 5 mg and ezetimibe 10 mg (n=54) or rosuvastatin 5 mg and ezetimibe 10 mg alone (n=54). The primary endpoint was LDL-C level at 2 weeks; cognitive safety was assessed using the Everyday Cognition (ECog) tool. RESULTS: Baseline LDL-C levels were similar between the 2 groups. At 2 weeks, LDL-C levels were lower in the evolocumab group compared to the non-evolocumab group (31±16 mg/dL vs. 63±17 mg/dL; p

Schlagwörter

Stichwörter der Autor:innen

Acute coronary syndromeCognitionEvolocumabPercutaneous coronary intervention

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea. yongcheol@yuhs.ac.
  • Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea. CHODK123@yuhs.ac.

ORCID-Profile: Ji Woong Roh, Oh-Hyun Lee, Yongcheol Kim, Seok-Jae Heo, Eui Im, Deok-Kyu Cho

Förderung

  • Daewoong Pharmaceutical Co., LTD.

Zitieren

APA

Roh, J. W., Lee, O. H., Kim, Y., Heo, S. J., Im, E., & Cho, D. K. (2026). Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Korean Circulation Journal, 56(4), 344. https://doi.org/10.4070/kcj.2025.0315

Vancouver

Roh JW, Lee OH, Kim Y, Heo SJ, Im E, Cho DK. Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Korean Circulation Journal. 2026;56(4):344. doi:10.4070/kcj.2025.0315

BibTeX
@article{Roh2026,
  author = {Roh, Ji Woong and Lee, Oh-Hyun and Kim, Yongcheol and Heo, Seok-Jae and Im, Eui and Cho, Deok-Kyu},
  title = {Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention},
  journal = {Korean Circulation Journal},
  year = {2026},
  volume = {56},
  number = {4},
  pages = {344},
  doi = {10.4070/kcj.2025.0315}
}
Kostenlos starten →